menu search

Here's why you should retain acadia (achc) in your portfolio

Diversified revenue base, improving top line, strategic expansion initiatives and joint ventures poise Acadia Healthcare (ACHC) well for growth....

March 15, 2023, 12:14 pm

Top funds can't get enough of this breakout ai stock

The best mutual funds have poured nearly $500 billion into cadence Design Systems, lifting the cloud an...

March 15, 2023, 8:00 am

3 elite dividend stocks down 30%+ to buy right now for decades of passive income

Crown Castle expects to grow its dividend at a 7% to 8% annual rate over the long term. Digital Realty has increased its payout every year since its p...

March 15, 2023, 7:45 am

Strength seen in acadia (acad): can its 5.0% jump turn into more strength?

Acadia (ACAD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the st...

March 15, 2023, 3:54 am

Mattel: visible top line growth cadence with revised capital allocation strategy

MAT 4Q22 results were disappointing, with a 22% drop in revenue, a 630 bps drop in gross margin, and a 35% drop in EPS, but 4Q22 POS was up. Looking f...

March 15, 2023, 3:49 am

Automatic data processing: a strategy for long-term wealth creation

ADP is a high-quality human capital management solution company that has delivered superb appreciation for shareholders over the last three decades wi...

March 15, 2023, 3:32 am

Why charlotte's web partnered with major league baseball to educate the world about cbd

Over a decade ago, Charlotte's Web created the CBD category and despite a roller coaster in the market, they remain the category leader today. As the ...

March 14, 2023, 12:15 pm

Canadian natural resources: 2 prongs to higher dividends

The Canadian Natural Resources Limited net debt target gets pushed back to later in 2023. Once Canadian Natural Resources' net debt target reaches...

March 14, 2023, 10:17 am

Crowdstrike may be a once-in-a-decade opportunity to supercharge your portfolio

The company is displaying decelerating revenue growth, despite being highly resistant to an economic slowdown. It has the best computer security solut...

March 14, 2023, 9:20 am

Is academy sports and outdoors a buy for 2023?

If results from Dick's Sporting Goods (NYSE: DKS) can be used as a guide, Academy Sports and Outdoors (NASDAQ: ASO) is a buy for 2023. Both stocks are...

March 14, 2023, 9:09 am

4 best profitable stocks to buy banking on net income ratio

MercadoLibre (MELI), iRadimed (IRMD), Northeast Community Bancorp (NECB) and AAON (AAON) have been selected as the top picks with a high net income ra...

March 14, 2023, 8:25 am

This warren buffett stock just got a huge upgrade

Apple's product revenue disappointed in the recent quarter, but services are at an all-time high. The company's installed base has doubled in under a ...

March 14, 2023, 8:14 am

Taiwan semiconductor: upside potential outweighs possible risks

Taiwan Semiconductor has consistently delivered stellar financial results with a track record of double-digit percentage topline growth in the last de...

March 14, 2023, 2:07 am

Vfva: is it value's time to shine?

The primary objective of the Vanguard U.S. Value Factor ETF is to invest in stocks with lower market valuations relative to fundamentals. Value and gr...

March 14, 2023, 2:07 am

Spgp etf: will it continue to outperform the market?

Invesco S&P 500 GARP ETF has significantly outperformed the market over the past decade by combining value and growth-factor loading. Its current valu...

March 13, 2023, 3:55 pm

Ingredion: higher margins and lower growth

Inflation could shift from a growth tailwind to a headwind, exacerbated by falling end-market demand. Like many peers, margins have been declining for...

March 13, 2023, 2:56 pm

Regional bank shares get clobbered as regulators step in

The turmoil that's engulfed bank stocks deepened Monday as investors rushed to reduce exposure to the industry, triggering a cascade of trading halts ...

March 13, 2023, 1:41 pm

Acadia's rare-disease drug to cost $575,000 to $595,000

Acadia Pharmaceuticals Inc. ACAD said its newly approved treatment for Rett syndrome has an annual list price ranging from $575,000 to $595,000, accor...

March 13, 2023, 12:11 pm

3 penny stocks with high growth potential in emerging markets

When we talk about a diversified portfolio, it would be a big mistake to ignore geographical diversification. In general, emerging markets will grow f...

March 13, 2023, 11:41 am

Acadia (acad) gets fda approval for daybue for rett syndrome

Acadia Therapeutics (ACAD) announces the FDA approval of its Rett Syndrome drug, trofinetide, for the treatment of adult and pediatric patients two ye...

March 13, 2023, 11:29 am


Search within

Pages Search Results: